Diampa LXR 5mg+2.5mg+1000mg Tablet – Triple Combination Empagliflozin, Linagliptin & Metformin XR
Diampa LXR 5mg+2.5mg+1000mg Tablet – Triple Combination Empagliflozin, Linagliptin & Metformin XR
Diampa LXR 5mg+2.5mg+1000mg Tablet – Triple Combination Empagliflozin, Linagliptin & Metformin XR
Description
Diampa LXR 5mg+2.5mg+1000mg Tablet – Complete Triple Therapy in One Extended-Release Tablet
Diampa LXR 5mg+2.5mg+1000mg Tablet is an advanced fixed-dose combination of Empagliflozin 5mg (SGLT2 inhibitor), Linagliptin 2.5mg (DPP-4 inhibitor), and Metformin XR 1000mg that delivers powerful, synergistic blood sugar control through three different mechanisms in a single once-daily dose. Ideal as initial triple therapy or when dual therapy is insufficient, it significantly lowers HbA1c, offers proven cardiovascular and kidney protection from the Empagliflozin component, and improves adherence with its convenient extended-release formulation.
